FSD Pharma Inc., a biotechnology company, operates in the pharmaceutical research and development business. Its lead candidate is FSD-201, an ultra-micronized palmitoylethanolamide for the treatment of inflammatory diseases. The company is also involved in the research and development of Lucid-Psych, a molecular compound identified for the treatment of mental health disorders; and Lucid-MS, a molecular compound identified for the treatment of neurodegenerative disorders. FSD Pharma Inc. was incorporated in 1998 and is headquartered in Toronto, Canada.
Stock data | 2024 | Change |
---|---|---|
Price | $4.20 | N/A |
Market Cap | $165.38M | N/A |
Shares Outstanding | 39.38M | N/A |
Employees | 17.00 | N/A |